Artificial intelligence in drug discovery: an interview with Ola Engkvist
At ELRIG Drug Discovery (9 ‒10 October 2018; London, UK) we spoke to Ola Engkvist, section head in the Hit Discovery Department at AstraZeneca (Cambridge, UK). In this interview, he explains the benefits of using artificial intelligence in the drug discovery process and the changes he believes it will bring to medicinal chemistry on the whole.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>